Clinical Markers and Outcomes of Neonates With Herpes Simplex Virus Deoxyribonucleic Acid Persistence in Cerebrospinal Fluid in Disseminated and Central Nervous System Infection

William R Otto; Angela L Myers; Barrett LaRussa; David W Kimberlin; Mary Anne Jackson

doi:10.1093/jpids/pix033

Clinical Markers and Outcomes of Neonates With Herpes Simplex Virus Deoxyribonucleic Acid Persistence in Cerebrospinal Fluid in Disseminated and Central Nervous System Infection

J Pediatric Infect Dis Soc. 2018 May 15;7(2):e30-e33. doi: 10.1093/jpids/pix033.

Authors

William R Otto¹, Angela L Myers^{1

2}, Barrett LaRussa³, David W Kimberlin³, Mary Anne Jackson^{1

2}

Affiliations

¹ Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri.
² Division of Infectious Diseases, Children's Mercy Hospital, Kansas City, Missouri.
³ Division of Pediatric Infectious Diseases, The University of Alabama at Birmingham.

PMID: 28510722
DOI: 10.1093/jpids/pix033

Abstract

We compared the clinical course of neonates with persistence of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) in the cerebrospinal fluid (CSF) after 21 days of treatment with high-dose acyclovir to that of neonates with clearance of the CSF after 21 days of therapy. Neonates with persistence of HSV DNA had a more severe clinical course with worse neurodevelopmental outcomes.

MeSH terms

Acyclovir / therapeutic use*
Antiviral Agents / therapeutic use*
Biomarkers / cerebrospinal fluid
Central Nervous System Infections / cerebrospinal fluid
Central Nervous System Infections / drug therapy*
Central Nervous System Infections / virology*
DNA, Viral / cerebrospinal fluid*
Encephalitis, Herpes Simplex / cerebrospinal fluid
Encephalitis, Herpes Simplex / drug therapy*
Encephalitis, Herpes Simplex / virology*
Female
Herpes Simplex / cerebrospinal fluid*
Humans
Infant, Newborn
Male
Retrospective Studies
Treatment Outcome

Substances

Antiviral Agents
Biomarkers
DNA, Viral
Acyclovir